Company intelligence / Profile preview

Kaprion

Montreal, Quebec, Canadakaprion.de ↗

Ownership: Private
Employees: ~225
Development stage: Commercial

Overview

CellCarta (formerly Caprion Biosciences) provides advanced proteomic and immune monitoring services to pharmaceutical and biotechnology clients worldwide. The company specializes in large-scale protein biomarker discovery/validation and comprehensive immune profiling using proprietary technologies such as ProteoCarta™ and ImmuneCarta®. In January 2021, it rebranded from Caprion-HistoGeneX to CellCarta after merging with HistoGeneX. It operates globally with CAP/CLIA-certified labs supporting precision medicine initiatives.

Modalities: ProteomicsFlow CytometryGenomicsHistopathology
Industry: Drug Discovery Services

Partnerships

Roche partnership on clinical trial proteomics readiness demonstrationnumerous biopharma clients globally

Beyond the preview

Go deeper on Kaprion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaprion.

Explore the full profile